• By Deanna Kamienski, Beth Allan, Amanda Micklus, Maureen Riordan, and Steven Muntner
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced August through September 2015.
Exiqon gets prostate cancer biomarkers from Aarhus Univ. Hosp.
A deal last year with Sanofi relieved Novavax of commercial costs for the COVID-19 vaccine Nuvaxovid, allowing the company to focus on R&D and finding partners for its other vaccines.
Sino Biopharm will pay almost $1bn to acquire what target LaNova’s CEO described as an “exploding” pipeline, which includes six clinical-stage candidates in the oncology area.
